98 related articles for article (PubMed ID: 2056222)
1. [The role of D-dimer in diagnosis of ovarian cancer].
Kanayama N
Nihon Sanka Fujinka Gakkai Zasshi; 1991 May; 43(5):485-8. PubMed ID: 2056222
[TBL] [Abstract][Full Text] [Related]
2. [The clinical significance of thrombin-antithrombin III complex (TAT) and fibrinogen and fibrin degradation products (FDP) levels in ovarian cancer].
Sawaguchi K; Hojo T; Nozaki S; Yabushita H; Noguchi M; Nakanishi M
Nihon Sanka Fujinka Gakkai Zasshi; 1992 Jan; 44(1):73-8. PubMed ID: 1541865
[TBL] [Abstract][Full Text] [Related]
3. [Tumor-associated antigens and fibrin derivatives as reaction products of ovarian cancer].
Schröck R; Hafter R; Schmid L; Babic R; Ulm K; Gössner W; Graeff H
Geburtshilfe Frauenheilkd; 1986 Jan; 46(1):1-10. PubMed ID: 2420679
[TBL] [Abstract][Full Text] [Related]
4. D-dimer as a tumor marker in pre-operative assessment of adnexal masses.
Worasethsin P; Narkwichean A
J Med Assoc Thai; 2013 Nov; 96(11):1395-400. PubMed ID: 24428087
[TBL] [Abstract][Full Text] [Related]
5. [Relationship between tumor markers and clinical symptoms in ovarian cancer].
Yakushiji M; Nishimura H
Rinsho Byori; 1992 Apr; 40(4):354-8. PubMed ID: 1593760
[TBL] [Abstract][Full Text] [Related]
6. [Preclinical and clinical studies on a tumor marker, galactosyltransferase associated with tumor (GAT), in ovarian cancer (second report)--clinical significance of GAT and comparison with other tumor markers].
Nozawa S; Udagawa Y; Ito K; Susumu N; Sasaki H; Aoki D
Gan To Kagaku Ryoho; 1993 Feb; 20(2):279-85. PubMed ID: 8434967
[TBL] [Abstract][Full Text] [Related]
7. Correlation between clinical stage of solid tumor and D dimer as a marker of coagulation activation.
Suega K; Bakta IM
Acta Med Indones; 2011 Jul; 43(3):162-7. PubMed ID: 21979281
[TBL] [Abstract][Full Text] [Related]
8. Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses.
Gadducci A; Baicchi U; Marrai R; Ferdeghini M; Bianchi R; Facchini V
Gynecol Oncol; 1996 Feb; 60(2):197-202. PubMed ID: 8631538
[TBL] [Abstract][Full Text] [Related]
9. [The diagnostic value of the assay of lactate dehydrogenese combined with other tumor markers in ovarian cancer].
Tang BJ; Li L; Xu J
Zhonghua Fu Chan Ke Za Zhi; 1994 Jun; 29(6):336-9, 381. PubMed ID: 8001406
[TBL] [Abstract][Full Text] [Related]
10. [Diagnosis of ovarian tumor by measuring tumor markers].
Fukatsu T; Nakashima N; Takeuchi J
Rinsho Byori; 1992 Feb; 40(2):133-8. PubMed ID: 1583785
[TBL] [Abstract][Full Text] [Related]
11. The measurement of plasma D-dimer (DD) levels in the follow-up of patients with ovarian cancer.
Gadducci A; Marrai R; Baicchi U; Ferdeghini M; Fanucchi A; Facchini V; Genazzani AR
Anticancer Res; 1995; 15(6B):2683-6. PubMed ID: 8669847
[TBL] [Abstract][Full Text] [Related]
12. Correlation of D dimer and factor VIII levels with histopathology in patients with breast carcinoma.
Khangarot SS; Gupta N; Goswami B; Hadke NS; Lal P; Gupta N; Khurana N
Cancer Biomark; 2010; 7(6):305-14. PubMed ID: 21694469
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of serum alpha-beta A immunoreactive inhibin and tumor-associated antigens CA125 and CEA in ovarian cancer.
Phocas I; Sarandakou A; Sikiotis K; Rizos D; Kalambokis D; Zourlas PA
Anticancer Res; 1996; 16(6B):3827-31. PubMed ID: 9042265
[TBL] [Abstract][Full Text] [Related]
14. [Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases].
Nozawa S; Udagawa Y; Sasaki H; Ito K; Akiya K; Terashima Y; Takamizawa H; Ohkura H; Fujimoto S; Hashimoto M
Gan To Kagaku Ryoho; 1994 May; 21(6):823-32. PubMed ID: 8185340
[TBL] [Abstract][Full Text] [Related]
15. Clinical usefulness of sialyl SSEA-1 antigen as tumor marker for ovarian cancer as compared with CA125, CA19-9, TPA, IAP, CEA and ferritin.
Yabushita H; Sawaguchi K; Hieda S; Ogawa A; Tomatsu A; Noguchi M; Ishihara M
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Feb; 41(2):217-24. PubMed ID: 2566639
[TBL] [Abstract][Full Text] [Related]
16. [The clinical value of tissue polypeptide antigen in ovarian carcinoma].
Wu L; Sun J; Wang X
Zhonghua Fu Chan Ke Za Zhi; 1998 Feb; 33(2):92-4. PubMed ID: 10682428
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of plasma D-dimer levels and serum VEGF levels in patients with hepatocellular carcinoma.
Tseng CS; Lo HW; Chen PH; Chuang WL; Juan CC; Ker CG
Hepatogastroenterology; 2004; 51(59):1454-8. PubMed ID: 15362775
[TBL] [Abstract][Full Text] [Related]
18. [The values of urine cysteine protein activity in the diagnosis of ovarian cancer].
Xi MR; Peng ZL; Cao ZY
Zhonghua Fu Chan Ke Za Zhi; 1994 Feb; 29(2):85-7, 123. PubMed ID: 8033632
[TBL] [Abstract][Full Text] [Related]
19. [Clinical value of a new serum tumor marker CA602 in ovarian cancers].
Suzuki M; Sekiguchi I; Ohwada M; Aida I; Tamada T
Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1454-60. PubMed ID: 2170549
[TBL] [Abstract][Full Text] [Related]
20. [Tumor marker CA 72-4 in ovarian cancer in comparison with CA 125 and D-dimer].
Schelling M; Jänicke F; Senekowitsch R; Lörken A
Gynakol Rundsch; 1991; 31 Suppl 2():286-9. PubMed ID: 1665138
[No Abstract] [Full Text] [Related]
[Next] [New Search]